Annexin A2 and cancer: A systematic review

  • Authors:
    • Maria V. Christensen
    • Claus K. Høgdall
    • Kirsten M. Jochumsen
    • Estrid V.S. Høgdall
  • View Affiliations

  • Published online on: November 8, 2017     https://doi.org/10.3892/ijo.2017.4197
  • Pages:5-18
Metrics: HTML 0 views | PDF 0 views
0

Abstract

Annexin A2 is a 36-kDa protein interfering with multiple cellular processes especially in cancer progression. The present review aimed to show the relations between Annexin A2 and cancer. A systematic search for studies investigating cancer and Annexin A2 expression was conducted using PubMed. Acute lymphoblastic leukaemia, acute promyelocytic leukaemia, clear cell renal cell carcinoma, breast, cervical, colorectal, endometrial, gastric cancer, glioblastoma, hepatocellular carcinoma, lung, multiple myeloma, oesophageal squamous cell carcinoma, ovarian cancer, pancreatic duct adenocarcinoma, prostate cancer and urothelial carcinoma were evaluated. Annexin A2 expression correlates with resistance to treatment, binding to the bone marrow, histological grade and type, TNM-stage and shortened overall survival. The regulation of Annexin A2 is of interest due to its potential as target for a more individualized cancer management.

Related Articles

Journal Cover

January 2018
Volume 52 Issue 1

Print ISSN: 1019-6439
Online ISSN:1791-2423

2016 Impact Factor: 3.079
Ranked #33/217 Oncology
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Christensen, M.V., Høgdall, C.K., Jochumsen, K.M., & Høgdall, E.V. (2018). Annexin A2 and cancer: A systematic review. International Journal of Oncology, 52, 5-18. https://doi.org/10.3892/ijo.2017.4197
MLA
Christensen, M. V., Høgdall, C. K., Jochumsen, K. M., Høgdall, E. V."Annexin A2 and cancer: A systematic review". International Journal of Oncology 52.1 (2018): 5-18.
Chicago
Christensen, M. V., Høgdall, C. K., Jochumsen, K. M., Høgdall, E. V."Annexin A2 and cancer: A systematic review". International Journal of Oncology 52, no. 1 (2018): 5-18. https://doi.org/10.3892/ijo.2017.4197